Skip to content

    RECURSION PHARMACEUTICALS (RXRX) stock price & financials

    View RXRX earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance31.7% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $26.08M
    $4.55M
    $14.74M
    $19.22M
    $5.17M
    -80.2%
    $35.54M
    +681.7%
    $6.47M
    -56.1%
    $7.67M
    -60.1%
    Strengthening
    Operating Profit
    -$98.35M
    -$183.77M
    -$191.37M
    -$176.23M
    -$172.20M
    -75.1%
    -$108.33M
    +41.0%
    -$128.50M
    +32.8%
    -$134.97M
    +23.4%
    Strengthening
    Net Profit
    -$95.84M
    -$178.91M
    -$202.49M
    -$171.90M
    -$162.25M
    -69.3%
    -$108.12M
    +39.6%
    -$117.50M
    +42.0%
    -$131.00M
    +23.8%
    Strengthening
    EPS
    $-0.34
    $-0.50
    $-0.41
    $-0.36
    -5.9%
    $-0.22
    +56.0%
    $-0.25
    +39.0%
    Strengthening
    Other Income
    $2.68M
    $4.87M
    -$11.28M
    $4.33M
    $9.95M
    +271.5%
    $232.0K
    -95.2%
    $6.40M
    $3.96M
    -8.5%
    Weakening
    Interest
    $553.0K
    $605.0K
    $508.0K
    $480.0K
    $833.0K
    +50.6%
    -$11.0K
    -101.8%
    $350.0K
    -31.1%
    $309.0K
    -35.6%
    Weakening
    Depreciation
    Profit before Tax
    -$95.67M
    -$178.90M
    -$202.65M
    -$171.90M
    -$162.25M
    -69.6%
    -$108.10M
    +39.6%
    -$122.11M
    +39.7%
    -$131.01M
    +23.8%
    Strengthening
    MarginsOPM
    -377.1%
    -4042.4%
    -1297.8%
    -916.8%
    -3327.6%
    -782.4%
    -304.8%
    +92.5%
    -1985.5%
    -53.0%
    -1759.7%
    -91.9%
    Weakening
    Tax
    -0.2%
    0.0%
    0.1%
    0.0%
    0.0%
    +100.0%
    -0.0%
    3.8%
    +4612.5%
    0.0%
    Strengthening
    ReturnsROIC
    4.1%
    7.7%
    8.7%
    7.4%
    7.0%
    +69.3%
    4.7%
    -39.6%
    5.1%
    -42.0%
    5.6%
    -23.8%
    Weakening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$75.17M$262.13M$285.12M$549.91M$391.56M$594.35M$743.29M$545.68M
    Short-Term Investments
    Total Current Assets$266.44M$534.72M$569.81M$438.14M$714.27M$812.85M$603.46M
    Net PP&E$25.97M$64.72M$121.45M$120.17M$206.94M$149.27M$129.89M
    Goodwill$801.0K$801.0K$801.0K$52.06M$148.87M$162.16M$160.35M
    Intangibles$1.69M$1.39M$1.31M$36.44M$335.86M$309.90M$282.89M
    Total Assets$298.58M$610.35M$701.29M$653.70M$1.45B$1.47B$1.21B
    LiabilitiesTotal Current Liabilities$23.10M$46.66M$100.27M$93.17M$187.47M$147.71M$119.89M
    Short-Term Debt
    Long-Term Debt$723.0K
    Long-Term Leases$0$44.42M$43.41M$67.25M$46.65M$39.19M
    Total Liabilities$56.56M$67.41M$215.48M$190.26M$413.82M$343.26M$297.67M
    EquityCommon Stock & APIC$0$2.0K$2.0K$2.0K$4.0K$5.0K$5.0K
    Retained Earnings-$213.60M-$400.08M-$639.56M-$967.62M-$1.43B-$2.08B-$2.32B
    Total Equity-$124.27M-$206.29M$542.94M$485.81M$463.44M$1.03B$1.13B$915.00M
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$57.04M-$45.40M-$158.61M-$83.52M-$287.78M-$359.17M-$371.81M-$350.48M
    Cash from Investing-$3.91M-$8.74M-$271.74M$193.25M-$10.23M$260.06M-$16.87M-$6.09M
    Cash from Financing$120.41M$246.13M$458.54M$154.34M$140.13M$304.12M$521.53M$378.61M
    SummaryCapital Expenditure-$3.91M-$5.83M-$39.80M-$37.06M-$11.96M-$13.70M-$6.47M-$1.79M
    Free Cash Flow-$60.95M-$51.23M-$198.41M-$120.58M-$299.74M-$372.87M-$378.28M-$352.27M
    FCF Margin-2628.4%-1293.0%-1949.4%-302.6%-672.4%-633.7%-506.5%-642.2%

    Ratios